NOVARTIS AG
NOVARTIS AG (NVSEF): 82 pipeline candidates. Updated within the last hour.
BioSniper Score
2-factor signal · derived from public data
N/A
N/A
Lead: Phase 3
82 candidates
N/A
N/A
A transparent, data-derived signal for NOVARTIS AGacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$276.4B
Cash
—
Quarterly Burn
—
Runway
—
Revenue
—
Pipeline (82 candidates)
| Drug | Phase |
|---|---|
| 111in-etn029 | Phase 1 |
| 13-valent pneumococcal conjugate vaccine | Phase 3 |
| 225ac-etn029 | Phase 1 |
| 23-valent pneumococcal polysaccharide vaccine | Phase 3 |
| abl001 200mg qd | Phase 3 |
| abl001 40mg bid | Phase 3 |
| abl001 80mg qd | Phase 3 |
| androgen deprivation therapy | Phase 1 |
| antiemetics & antinauseants | Phase 1 |
| asciminib single agent | Phase 3 |
Showing 10 of 82 candidates. Sign up for full pipeline.
Frequently asked questions
How many drug candidates are in NOVARTIS AG's pipeline?
NOVARTIS AG (NVSEF) has 82 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is NOVARTIS AG's lead drug candidate?
NOVARTIS AG's most advanced tracked candidate is 111in-etn029 (Phase 1) for Small Cell Lung Carcinoma.
What is NOVARTIS AG's market capitalization?
NOVARTIS AG's market capitalization is approximately $276.4B.
Who is the CEO of NOVARTIS AG?
Dr. Vasant Narasimhan M.D. is the chief executive officer of NOVARTIS AG (NVSEF).
Get the full picture on NOVARTIS AG
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.